NCT04501926 (GEMAS) is a clinical trial in Asthma, sponsored by Maria Pino-Yanes.

Who is sponsoring NCT04501926?

NCT04501926 is sponsored by Maria Pino-Yanes.

What condition does NCT04501926 study?

NCT04501926 studies Asthma, Asthma Attack.

Is NCT04501926 still recruiting?

NCT04501926 is currently status unknown. Last updated 17 May 2022.

Last reviewed 2022-05-17 · How we verify

NCT04501926: GEMAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genomics and Metagenomics of Asthma Severity

Status unknown Last updated 17 May 2022

What this trial tests

trial in Asthma in 300 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Maria Pino-Yanes
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 March 2018
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	6 locations across Spain

Conditions studied

Asthma — all drugs for Asthma →
Asthma Attack — all drugs for Asthma Attack →

Sponsor

Maria Pino-Yanes

Who can join

Adults 8 to 85, any sex, with Asthma or Asthma Attack. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Genomics and Metagenomics of Asthma Severity (GEMAS) study aims to assess the role of genomics, the microbiome, and the interaction between them in the development of asthma exacerbations in European patients with asthma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Genomics and Metagenomics of Asthma Severity (GEMAS) Study: Rationale and Design.
Perez-Garcia J, Hernández-Pérez JM, González-Pérez R, Sardón O, et al · · 2020 · cited 11× · PMID 32933076 · DOI 10.3390/jpm10030123

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04501926 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maria Pino-Yanes
Last refreshed: 17 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04501926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing